Biotechnology
Method notes, results and company news from Novasign.
BioprocessBioprocess DevelopmentMar 20, 2026De‑Risking Bioprocess Scale‑Up: Predictive Modeling for Reliable Fermentation and Cell Culture Manufacturing
Scaling a bioprocess from laboratory development to industrial manufacturing is one of the most critical, and risky steps in biotechnology. For contract development and manufacturing organizations (CDMOs), large pharmaceutical companies, industrial biotechnology producers, and emerging sectors such…
BioprocessBioprocess DevelopmentMar 20, 2026Autonomous Continuous Biomanufacturing: Closing the Gap Between Process Development and Production
Continuous biomanufacturing has long been considered one of the most promising approaches to increase productivity, reduce facility footprint, and enable more sustainable bioprocessing.
BioprocessBioprocess DevelopmentMar 20, 2026Next‑Generation Media Development: How Modeling Reduces Cost and Accelerates Bioprocess Optimization
Media composition is one of the least transparent elements in modern cell culture bioprocess development. Whether producing monoclonal antibodies, recombinant proteins, industrial enzymes, or cultivated food products, the composition of the cell culture or fermentation media directly determines…
BioprocessBioprocess DevelopmentApr 3, 2025Hybrid Modeling Meets Filtration: Optimizing UF and DF in Monoclonal Antibody Processing
Producing monoclonal antibodies often involves the challenge of balancing high protein concentrations with the risk of membrane fouling or poor recovery. Our innovative workflow captures detailed experimental data from a single experiment to characterize key variables like membrane behavior and…
- Bioprocess DevelopmentBiotechnologyJul 28, 2021
Antleron and Novasign to join forces in ATMP Modeling
Advanced therapy medicinal products (ATMPs) are targeted therapies based on genes, cells, or tissues that deliver a therapeutic benefit to a patient-specific population and often treat rare diseases or improve upon existing treatments. The global ATMP market is expected to reach approximately 21.2…
BiotechnologyHybrid ModelingOct 15, 2020Novasign Soft Sensing Technology at Siemens’ LivingLab
Innovative tools to monitor important upstream bioprocess variables in real-time, such as biomass, are of high interest for manufacturers. Typically, to get these values, a sample must be drawn, processed, and analyzed. These steps lead to an inevitable time delay, which makes this desired…
Bioprocess DevelopmentBiotechnologyApr 3, 2020COVID-19: An example of why we need robust and fast process development
The current worldwide situation regarding the COVID-19 pandemic has shown all of us how vulnerable our daily life can be. In the case of such an unpredicted event, everyone must make trade-offs, personal and economic. That is why in such situations it is of the highest priority to react fast and…
Bioprocess DevelopmentBiotechnologyMar 18, 2020COVID-19, Home Office and a New Toolbox Release
Due to the COVID-19 outbreak, the Austrian government decided to minimize unnecessary human interaction. These actions will reduce the number of new infections and flattens the curve, providing enough time for the health system to cope with these new unmet challenges. Hence, Novasign also followed…
Bioprocess DevelopmentBiotechnologyOct 18, 2019The Hybrid Modeling Summer School 2019
From the 25th to the 27th of September, Novasign co-hosted the 4th hybrid modeling summer school in Lisbon, Portugal. After a very detailed introduction to hybrid modeling by Prof. Rui Oliveira and Moritz von Stosch, the 41 participants were introduced to the pre-release Novasign hybrid modeling…
BiotechnologyHybrid ModelingMar 27, 2019Bioprocessing Europe Lisbon
Last week we have been to Bioprocessing Europe in Lisbon. The conference was organized in a brought manner, offering both, an up- and downstream processing stream, as well as a gene and cell therapy stream. With more than 100 experts presenting their current bleeding and cutting edge technology,…
- BiotechnologyFDANov 7, 2018
Reducing the costs of biopharmaceuticals: a bioprocess development approach
In 2018 the generated revenue by biopharmaceuticals is estimated to be approximately 200 b$! Although this is an incredibly high number, this revenue will only be generated by approximately 20 metric tons of biopharmaceuticals! Or in other words: one gram of biopharmaceutics sells around 10000 €.…
BioprocessBiotechnologyAug 8, 2018Best talk @10th ÖGMBT Annual Meeting
From the 17th to the 20th of September, the 10th ÖGMBT Annual Meeting took place in Vienna. Over 450 participants including employees from large pharmaceutical companies, equipment vendors and students met at the campus of the University of Vienna. They presented the latest results in different…
12 of 12 posts